Function
Human Immunodeficiency Virus (HIV) is the cause of Acquired Immunodeficiency Syndrome (AIDS). HIV synthesizes all of its proteins as one long chain. This long chain must be cut into individual component proteins. This hydrolysis reaction is catalyzed by . Since this isn't a process that is used for normal human proteins, it is a target for medications that treat HIV and AIDS.
Structure of HIV-1 Protease
The X-ray crystallography structure of HIV-1 protease[1][2] reveals that it is composed of , each consisting of 99 amino acid residues. The subunits come together in such as way as to . This tunnel is of critical importance because this is where the long protein chain substrate binds to HIV protease. You may be wondering how a polyprotein makes its way into the tunnel, as the to let it in. The key is the two flexible flaps on the top of the tunnel that to enter the tunnel. The flaps , shifting from an open to a closed conformation to bind the target in an appropriate conformation for cleavage.
The of HIV protease is mostly beta strands in alternating directions to form a structure known as a . In this color scheme, the N terminus for each protein chain is blue, and moves through the rainbow of colors (light blue, green, yellow, and orange) to the C terminus, shown in red.
How HIV Protease works
HIV protease is categorized as an Aspartate Protease. This means that are required for its function. In HIV protease, one aspartic acid from each protein chain interacts with the to position it in a way that water can break the peptide bond.
How drugs inhibit HIV Protease
The first protease inhibitor approved by the FDA for the treatment of HIV was . It inhibits HIV protease by , preventing the binding of polyproteins. Its chemical structure mimics the tetrahedral intermediate of the hydrolytic reaction, thereby .[3] Since Saquinavir doesn't have a bond that can be broken by water, it gets "stuck" in the active site, and prevents the actual HIV protein from being able to bind to the enzyme. Unfortunately, variations in the sequences of HIV protease provide resistance to saquinaivr, including the mutation of [4]. New generations of protease inhibitors such as and block HIV Protease in similar ways.
